-
Regarding proposed election of board members24 Apr 2015
-
Hexvix® in Medical News TodayMonday 30 March 2015: Medical News Today features article on Hexvix fluorescence-guided bladder resection: Recently published data demonstrate favorable overall survival outcome in bladder cancer patients31 Mar 2015
-
Hexvix® blue-light flexible cystoscopy in the outpatient setting: presentation at European Association of Urology annual meetingHexvix blue-light flexible cystoscopy allows for better identification and management of recurrent low-grade tumors in the outpatient setting, providing clinical, patient, and economic benefits.23 Mar 2015
-
New study shows PDD Hexvix and immediate post-TURB chemoprophylaxis reduces the risk of recurrence and number of follow-up procedures in NMIBCOslo, Norway, 12 March 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that a study published in Scandinavian Journal of Urology concludes that fluorescence cystoscopy with Hexvix® and immediate post-transurethral resection of the bladder (TURB) chemoprophylaxis effectively reduced the recurrence risk and the number of follow-up TURB procedures under clinical routine conditions.12 Mar 2015
-
NICE publishes bladder cancer guideline, recommending photodynamic diagnosis to improve detectionOslo, Norway, 2 March 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that the National Institute for Health and Care Excellence (NICE) in the UK has published its first guidelines on bladder cancer, recommending photodynamic diagnosis for improved detection of bladder cancer.(1) NICE makes evidence-based recommendations for healthcare, with the aim of improving treatment and reducing variations in care.02 Mar 2015
-
Photocure ASA - Results for fourth quarter and full year 2014Oslo, Norway, 12 February 2015: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for fourth quarter and full year 2014.12 Feb 2015
-
New data provide evidence that Hexvix® can improve the overall survival in bladder cancer patientsIn a retrospective study Hexvix fluorescence–guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light.29 Jan 2015
-
PHOTOCURE ANNOUNCES END OF PHASE 2 STATUS ACHIEVED FOR CEVIRA IN U.S.Cevira® advances towards Phase 3 for treatment in patients with cervical high-grade lesions (HSIL)07 Jan 2015
-
Exercise of employee share optionsKjetil Hestdal, President and CEO of Photocure, has today, December 23th 2014, exercised 37 500 share options in Photocure ASA, at the strike price of NOK 18.30.23 Dec 2014
-
2014 business performance goals update22 Dec 2014
-
Focus on Cevira®: Review article published in Expert Opinion of Investigational DrugsReview article highlights Cevira® as a promising tissue sparing alternative to observation and surgical procedures in patients with cervical precancerous lesions19 Dec 2014
-
Implementing Hexaminolevulinate HCl Blue Light Cystoscopy: A Nursing PerspectiveUS Nurses’ perspectives on successful implementation of blue-light cystoscopy published in the AORN Journal (November 2014)28 Nov 2014
-
New study from Germany on Photodynamic Diagnosis using flexible scopes“Photodynamic Diagnosis of the Urinary Bladder using Flexible Instruments –Ready for the Outpatient Setting?”21 Nov 2014
-
Results for third quarter and the first nine months 2014Oslo, Norway, 6 November 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for third quarter and the first nine months 2014.06 Nov 2014
-
Cevira® data published in American Journal of Obstetrics & GynecologyPhase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.04 Nov 2014
-
Cevira® featured in the Nolato MagazineCevira® was recently presented in the Nolato Magazine no 25. Oct 2014.30 Oct 2014
-
Results of the Cevira Phase 2b presented at DGGGThe results of the Cevira Phase 2b were presented 10.10.2014 at the annual German gynecology meeting (DGGG) in Munich, one of the key gynecology conferences in Europe with nearly 2000 participants.10 Oct 2014